Further analysis demonstrated that among HR positive breast cancer patients, HER2-low patients typically presents a lower incidence of grade III tumors, a lower Ki-67 proliferation index, and fewer TP53 mutations compared with HER2-zero patients. Here, ERBB2 is linked to breast cancer.